American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 603.e1-603.e7 , December 2009

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting

Presented at a meeting of gynecologic oncologists within the Norwegian Forum for Oncology, Bergen, Norway, Nov. 21, 2008.

  • Elisabeth Wik, MD

      Affiliations

    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway
    • Corresponding Author InformationReprints: Elisabeth Wik, MD, Institute of Clinical Medicine, Section for Gynecology and Obstetrics, University of Bergen, Haukeland University Hospital, 5021 Bergen, Norway
    • ,
  • Jone Trovik, MD

      Affiliations

    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway
    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Ole E. Iversen, MD, PhD

      Affiliations

    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway
    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Ingeborg B. Engelsen, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Ingunn M. Stefansson, MD, PhD

      Affiliations

    • Section of Pathology, The Gade Institute, University of Bergen, Bergen, Norway
    • Department of Pathology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Liv C. Vestrheim, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Hans K. Haugland, MD, PhD

      Affiliations

    • Department of Pathology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Lars A. Akslen, MD, PhD

      Affiliations

    • Section of Pathology, The Gade Institute, University of Bergen, Bergen, Norway
    • Department of Pathology, Haukeland University Hospital, Bergen, Norway
    • ,
  • Helga B. Salvesen, MD, PhD

      Affiliations

    • Institute of Clinical Medicine, University of Bergen, Bergen, Norway
    • Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway

Received 26 February 2009 ,Revised 20 May 2009 ,Accepted 14 July 2009.

References 

  1. Cancer Registry of Norway. Cancer in Norway 2005. Special edition. Oslo, Norway: Institute of Population-Based Cancer Research; 2005;
  2. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505
  3. Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Apmis. 2002;110:673–689
  4. Hogberg T, Fredstorp-Lidebring M, Alm P, et al. A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology (Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer). Int J Gynecol Cancer. 2004;14:437–450
  5. Lim P, Aquino-Parsons CF, Wong F, et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol. 1999;73:191–195
  6. Mangili G, Montoli S, De Marzi P, et al. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol. 2008;19:1278–1283
  7. Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol. 1986;155:770–776
  8. Hall PA. DNA ploidy analysis in histopathology (DNA ploidy studies in pathology—a critical appraisal). Histopathology. 2004;44:614–620
  9. Salvesen HB, Iversen OE, Akselen LA. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res. 1998;4:2779–2785
  10. The Cancer Registry of Norway. Cancer in Norway, 1996. 1st ed.. Oslo, Norway: Institute for Epidemiological Cancer Research; 1999;
  11. Announcement (FIGO stage, 1988 revision). Gynecol Oncol. 1989;35:125–127
  12. Silverberg SG, Kurman RJ, Nogales F, et al. Tumors of the uterine corpus. In:  Tavassoli FA,  Devilee P editor. Tumours of the breast and female genital organs (World Health Organization classification of tumours: pathology and genetics). 5th ed.. Lyons, France: IACR Press, Inc; 2003;p. 217–258
  13. Engelsen IB, Stefansson I, Akslen LA, Salvesen HB. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol. 2006;195:979–986
  14. Iversen OE, Utaaker E, Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand. 1988;67:531–537
  15. Barlogie B, Raber MN, Schumann J, et al. Flow cytometry in clinical cancer research. Cancer Res. 1983;43:3982–3997
  16. Friedlander ML, Hedley DW, Taylor IW. Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol. 1984;37:961–974
  17. Fox H. Ploidy in gynaecological cancers. Histopathology. 2005;46:121–129
  18. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet. 1996;53:23–30
  19. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer. 1994;73:2380–2385
  20. Nordstrom B, Strang P, Bergstrom R, Nilsson S, Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma (Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction). Cancer. 1996;78:1942–1951
  21. Terada K, Mattson D, Goo D, Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol. 2004;95:483–487
  22. Konski A, Domenico D, Tyrkus M, et al. Prognostic characteristics of surgical stage I endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys. 1996;35:935–940
  23. Mariani A, Sebo TJ, Webb MJ, et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev. 2003;27:434–441
  24. Orbo A, Rydningen M, Straume B, Lysne S. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in northern Norway. Int J Gynecol Cancer. 2002;12:49–56
  25. Sorbe B, Risberg B, Frankendal B. DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol. 1990;38:22–27
  26. Braly PS. Flow cytometry as a prognostic factor in endometrial cancer—what does it add?. Gynecol Oncol. 1995;58:145–147
  27. Lindahl B, Alm P, Fernø M, et al. Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation. Anticancer Res. 1987;7:791–797
  28. Nordstrøm B, Strang P, Lindgren A, Bergstrøm R, Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications?. Int J Gynecol Pathol. 1996;15:191–201
  29. Pradhan M, Abeler VM, Danielsen HE, Trope CG, Risberg BÅ. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol. 2006;19:1227–1235
  30. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404–1411
  31. Susini T, Amunni G, Molino C, et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called ‘low-risk' patients with well and moderately differentiated tumors. Cancer. 2007;109:882–890
  32. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23:3668–3675
  33. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–136
  34. Van den Bruel A, Cleemput I, Aertgeerts B, Ramaekers D, Buntinx F. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol. 2007;60:1116–1122
  35. Herman CJ. Cytometric DNA analysis in the management of cancer (Clinical and laboratory considerations). Cancer. 1992;69:1553–1556
  36. Podratz KC, Wilson TO, Gaffey TA, Cha SS, Katzmann JA. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol. 1993;168:1206–1213

 This study was supported in part by Helse Vest and a legacy of Harald Andersen to the Norwegian Cancer Society.

 Cite this article as: Wik E, Trovik J, Iversen OE, et al. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol 2009;201:603.e1-7.

PII: S0002-9378(09)00816-3

doi: 10.1016/j.ajog.2009.07.029

American Journal of Obstetrics & Gynecology
Volume 201, Issue 6 , Pages 603.e1-603.e7 , December 2009

Article Tools

* Image Usage & Resolution